Pipelinepharma - pipeline intelligence and pharmaceutical dossier sourcing platform, providing visibility into existing and future competition across a broad range of pharmaceutical dossiers — including EU and US CTDs — covering generics (Gx), biosimilars, innovative medicines, and finished dosage formulations. We help pharmaceutical companies de-risk portfolio, licensing, and investment decisions by revealing the true competitive landscape — including competitive density, future market pressure, post-LOE supply predictability, upcoming competition, and expected price erosion — based on aggregated, permission-based data, with strict respect for IP ownership and confidentiality. Pipeline intelligence supports strategy alignment from portfolio planning through commercial execution, enabling informed, risk-aware decision-making across strategy, portfolio, R&D, and business development teams. For companies with a defined product or market focus, Pipelinepharma provides a separate sourcing and execution capability, enabling direct engagement with 2,000+ verified dossier owners, manufacturers, and CDMOs, with visibility across 90,000+ pharmaceutical product dossiers. All interactions take place without intermediaries or brokerage fees, enabling transparent and efficient B2B collaboration. 📧 Let’s talk: support@pipelinepharma.com
Looking for a particular Pipelinepharma employee's phone or email?
The Pipelinepharma annual revenue was $1 million in 2026.
Mindaugas Zagorskis is the Founder and CEO of Pipelinepharma.
10 people are employed at Pipelinepharma.
Pipelinepharma is based in New York, New York.
The NAICS codes for Pipelinepharma are [325, 32, 3254, 32541].
The SIC codes for Pipelinepharma are [28, 283].